|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
ES2319539T3
(es)
*
|
2003-09-17 |
2009-05-08 |
Janssen Pharmaceutica Nv |
Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
|
|
AU2011253635B2
(en)
*
|
2003-09-17 |
2014-10-30 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds
|
|
US7473783B2
(en)
|
2003-12-17 |
2009-01-06 |
Sgx Pharmaceuticals, Inc. |
Bicyclic pyrazolo protein kinase modulators
|
|
WO2005123111A2
(en)
*
|
2004-06-21 |
2005-12-29 |
Exelixis, Inc. |
Maxs as modifiers of the axin pathway and methods of use
|
|
CA2581454A1
(en)
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
ES2622493T3
(es)
*
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
AU2007238608A1
(en)
|
2006-04-14 |
2007-10-25 |
Massachusetts Institute Of Technology |
Identifying and modulating molecular pathways that mediate nervous system plasticity
|
|
PL2044056T3
(pl)
*
|
2006-07-14 |
2013-01-31 |
Novartis Ag |
Pochodne pirymidyny jako inhibitory ALK-5
|
|
RU2009120622A
(ru)
*
|
2006-11-01 |
2010-12-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Трициклические гетероарильные соединения в качестве ингибиторов янус-киназы
|
|
WO2008135786A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Astrazeneca Ab |
Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
AU2009238590A1
(en)
*
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
JP5063815B2
(ja)
*
|
2008-11-25 |
2012-10-31 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
|
|
WO2010093808A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
US8663210B2
(en)
|
2009-05-13 |
2014-03-04 |
Novian Health, Inc. |
Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
|
|
JO3030B1
(ar)
*
|
2009-06-26 |
2016-09-05 |
Galapagos Nv |
مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
|
|
CN102471339A
(zh)
*
|
2009-07-15 |
2012-05-23 |
雅培制药有限公司 |
激酶的吡咯并吡啶抑制剂
|
|
CN106420756A
(zh)
*
|
2009-07-28 |
2017-02-22 |
里格尔药品股份有限公司 |
抑制jak途径的组合物和方法
|
|
JP2013503189A
(ja)
*
|
2009-08-28 |
2013-01-31 |
アレイ バイオファーマ、インコーポレイテッド |
Ｒａｆ阻害化合物およびその使用方法
|
|
UY33213A
(es)
*
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
WO2013113762A1
(en)
|
2012-01-31 |
2013-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
|
|
DK2830662T3
(da)
*
|
2012-03-29 |
2019-01-02 |
Univ Columbia |
Fremgangsmåder til behandlng af hårtabsforstyrrelser
|
|
MX371331B
(es)
|
2012-04-24 |
2020-01-27 |
Vertex Pharma |
Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
JP6408569B2
(ja)
|
2013-10-17 |
2018-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
|
|
CN110229142A
(zh)
*
|
2014-04-04 |
2019-09-13 |
希洛斯医药品股份有限公司 |
细胞周期蛋白依赖性激酶7(cdk7)的抑制剂
|
|
WO2016109684A2
(en)
*
|
2014-12-30 |
2016-07-07 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis b infections
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
|
EP3676264A1
(en)
*
|
2017-08-28 |
2020-07-08 |
Acurastem Inc. |
Pikfyve kinase inhibitors
|
|
CN108586341B
(zh)
*
|
2018-05-25 |
2020-05-08 |
天津商业大学 |
酰胺类化合物和其药用盐及其制备方法和药物用途
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3955920A1
(en)
|
2019-04-16 |
2022-02-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114605390B
(zh)
*
|
2020-12-04 |
2024-08-16 |
上海凌达生物医药有限公司 |
具有cdk激酶抑制活性的化合物、其药物组合物和用途
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|